The present invention relates to ansamycin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine.
US8492370B2
申请人:——
公开号:US8492370B2
公开(公告)日:2013-07-23
Heat Shock Proteins Revisited: Using a Mutasynthetically Generated Reblastatin Library to Compare the Inhibition of Human and<i>Leishmania</i>Hsp90s
Heatshockprotein (Hsp) inhibition in parasites: New reblastatin derivatives, prepared by mutasynthesis complemented with a library of other Hsp inhibitors, were evaluated in cell‐based and in in vitro ATP displacement assays, the latter utilising purified human HsHsp90 and LbHsp90 from L. braziliensis. The study paves the way for finding selective inhibitors of parasitic heatshockproteins.